Dr. Patrick J. Eulitt, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Eastern Virginia Medical School (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 669
Licensed in Colorado since 2020, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: Eastern Virginia Medical School
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CO license DR.0063766 (first issued 2020; active) - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Adventhealth Littleton Littleton, CO
- Adventhealth Castle Rock Castle Rock, CO
- Sky Ridge Medical Center Lone Tree, CO
- HCA Healthone Presbyterian St. Lukes Denver, CO
Medical groups
- Rocky Mountain Cancer Centers LLP (132 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 669
- Services billed
- 145,514
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, pembrolizumab, 1 mg | 22,000 | 22 |
| Injection, fosaprepitant, 1 mg | 17,400 | 40 |
| Injection, iron sucrose, 1 mg | 14,100 | 28 |
| Injection, lanreotide, 1 mg | 9,780 | 23 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 7,650 | 11 |
| Injection, daratumumab, 10 mg and hyaluronidase-fihj | 6,660 | 11 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 3,410 | 40 |
| Injection, dexamethasone sodium phosphate, 1 mg | 3,155 | 76 |
| Injection, denosumab, 1 mg | 3,060 | 17 |
| Injection, palonosetron hcl, 25 mcg | 1,690 | 56 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Lone Tree, CO | 94 |
| Prednisone Other prescribers in Lone Tree, CO | 58 |
| Prochlorperazine Maleate Other prescribers in Lone Tree, CO | 39 |
| Diphenoxylate-Atropine (diphenoxylate hcl/atropine) Other prescribers in Lone Tree, CO | 33 |
| Ondansetron Odt (ondansetron) Other prescribers in Lone Tree, CO | 31 |
| Abiraterone Acetate | 28 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in Lone Tree, CO | 28 |
| Duloxetine Hcl Other prescribers in Lone Tree, CO | 24 |
| Xtandi (enzalutamide) | 21 |
| Hydroxyurea Other prescribers in Lone Tree, CO | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 2 payments worth $40.81 in total to this clinician.
| Iovance Biotherapeutics, Inc. | $40.81 |
|---|
| Food and Beverage | $40.81 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $384,769 in research payments for these studies, mostly to the institutions running them.
- Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience, Inc. · Completed · NCT05103358 - An interventional phase 3 doubleblind randomized study to evaluate the efficacy and safety of PF08634404 in combination with chemotherapy versus bevacizumab in combination with chemotherapy in treatmentnaÏve participa…
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.